Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The current state of molecularly targeted drugs targeting HGF/Met.

Japanese journal of clinical oncology - 1 Jan 2014

Yano Seiji, Nakagawa Takayuki

Abstract excerpt

Met is a tyrosine kinase that has hepatocyte growth factor as its ligand. Met plays a major role in cell growth, migration and morphological changes. Overexpression of hepatocyte growth factor and Met and mutations and amplification of MET have been noted in many forms of cancer and are reportedly correlated with cancer progression and a poor prognosis. Over the past few years, these molecules have attracted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Aminopyridines
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drugs, Investigational

Share to Hepatocyte Growth Factor

Share to Pyrrolidinones

Share to Quinolines

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Identifiers

PMID: 24371262
DOI: 10.1093/jjco/hyt188

Genes

HGF
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The current state of molecularly targeted drugs targeting HGF/Met.PMID 24371262Read ↗

Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applicationsSemantic proximity Read ↗

Targeting the hepatocyte growth factor/Met pathway in cancer.Semantic proximity Read ↗

Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in CancerSemantic proximity Read ↗

Targeting the c-Met Signaling Pathway in CancerSemantic proximity Read ↗

The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesisSemantic proximity Read ↗

Biomarker development in MET-targeted therapy.Semantic proximity Read ↗

Cancer therapy: can the challenge be MET?Semantic proximity Read ↗

The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.Semantic proximity Read ↗

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunitiesSemantic proximity Read ↗

Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.Semantic proximity Read ↗

MET receptor tyrosine kinase as a therapeutic anticancer target.Semantic proximity Read ↗

MET as a possible target for non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.